Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
SAGE Therapeutics ( (SAGE) ) has shared an announcement.
Sage Therapeutics announced its strategic focus for 2025 at the J.P. Morgan Healthcare Conference, emphasizing the commercialization of ZURZUVAE for postpartum depression. The company also received a non-binding acquisition proposal from Biogen Inc., which could have significant implications for its future operations and market positioning.
More about SAGE Therapeutics
Sage Therapeutics is a biopharmaceutical company specializing in developing treatments for brain health disorders. They focus on products for neurodevelopmental disorders and neuropsychiatry, with a significant emphasis on addressing postpartum depression (PPD) through their product ZURZUVAE.
YTD Price Performance: -3.98%
Average Trading Volume: 1,068,589
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $339.5M
Learn more about SAGE stock on TipRanks’ Stock Analysis page.
